glp 1 name brands 2025’s Breakthrough GLP-1 Obesity Treatments: Top Companies & Innovations GLP-1 Shortage = Over -
Description
Gasbjerg LS, Helsted MM, Hartmann B, Sparre-Ulrich AH, Veedfald S, Stensen S, Lanng AR, Bergmann NC, Christensen MB, Vilsboll T, et al

The severity of these conditions and increasing news coverage has driven rapid growth in the MDL, with more than 100 new lawsuits filed in October 2025 alone

[DOI] [PMC free article] [PubMed] [Google Scholar] 7.Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al

doi: 10.1016/J.CMET.2017.04.009
Diabetes - GLP-1 agonists should be primarily considered in patients with type 2 diabetes with suboptimal glycaemic control despite maximal tolerated dose of metformin (+/- other agents) especially where weight loss is desired and/or significant stroke risk is present

B., Exenatide Use in the Management of Type 2 Diabetes Mellitus, Pharmaceuticals 3 (2010): 25542567
